DEENOVA
20.6.2022 06:02:09 CEST | Business Wire | Press release
Deenova today disclosed that it expanded its market dominance in France with another net new UniHA competitive award for its D3 ACCED mechatronic solution at Centre Hospitalier de Mayotte in French overseas departments. Additionally, Deenova announced a new competitive tender win at GHPSO Creil & Senlis also for its market leading D3 ACCED mechatronic robot through its partnership with another premier hospital group, RESAH . Separately, Deenova is pleased to simultaneously report additional add-on sales of its unique ASTUS cabinets and D3 ACCED to existing Deenova customer Institute Nationale des Invalides in Paris, also through its UniHA partnership.
Loïc Bessin , Managing Director of Deenova in France stated: “Bringing together net new business tender wins at Centre Hospitalier de Mayotte and GHPSO Creil & Senlis for our D3 ACCED mechatronic solutions, while at the same time earning the trust of additional sales to previous Deenova ASTUS customers such as Institute Nationale des Invalides is steady evidence of Deenova France unparalleled success in our industry, undoubtedly showing the market a high level of reliable customer satisfaction in France.”
Christophe Jaffuel , Deenova Chief Commercial Officer, added: “A new milestone for Deenova is reached: expansion beyond the European continent, a great ongoing incentive for our sales teams. I am very appreciative for the important and yearly contribution that both UniHA and RESAH ongoing multi-year tender awards means to Deenova in France and now beyond, renewing its past commitment to Deenova market-leading Unit-Dose solutions. I look forward to continuing the outstanding cooperation with UniHA and RESAH in the near future.”
Centre Hospitalier de Mayotte , a public health establishment with 543 beds, is the only hospital in the overseas Department of Mayotte . It is located in the northern part of the Mozambique Channel in the Indian Ocean off the coast of Southeastern Africa. It provides both hospital care and out-patient care with 4 localized care and childbirth centers (North, Centre, South and Petite-Terre) of intermediate level, providing general consultations and a 24-hour medical service and 7 days a week.
GHPSO Creil & Senlis , located just 30 minutes from Paris CDG airport , offers a complete emergency service: Adult, Paediatric and Gyneco-obstetrics with 584 full hospital beds, 46 day hospitalization places, 21 haemodialysis stations, and on the other hand an offer in Follow-up and Rehabilitation Care (SSR) with 32 beds, in accommodation with 73 Long-Term Care Unit beds (USLD), 90 beds in an Accommodation Establishment for Dependent Elderly Persons (EHPAD) and 12 places in Alzheimer's day centre, i.e. a total of 858 beds. The SMUR unit intervenes at the request of the SAMU de l’Oise.
Institute Nationale des Invalides is placed under the supervision of the French Government Ministry of Defense and Veterans Affairs. It is responsible for welcoming veterans who are victims of severe handicaps linked to war wounds. It includes three complementary centers: the Pensioners’ Center, the Post-Traumatic Rehabilitation Center and the Center for Studies and Research on Equipment for the Handicapped. A total of 91 single rooms are fully equipped for patients in the Paris metropolitan area.
UniHA , the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services, and to preserve equal access to care.
RESAH is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova ’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220619005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom